
Joseph Cheriyan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/919368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease. , 2022, 1, .		12
2	Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovascular Disorders, 2022, 22, 49.	0.7	14
3	Niclosamide—A promising treatment for COVIDâ€19. British Journal of Pharmacology, 2022, 179, 3250-3267.	2.7	31
4	Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. Journal of Molecular and Cellular Cardiology, 2022, 167, 92-96.	0.9	19
5	Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease. Age and Ageing, 2021, 50, 795-801.	0.7	12
6	Baricitinib set to join the Covid-19 therapeutic arsenal?. Rheumatology, 2021, 60, 1585-1587.	0.9	7
7	Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. BMJ Open, 2021, 11, e037457.	0.8	4
8	Quantitative ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD. ERJ Open Research, 2021, 7, 00699-2020.	1.1	2
9	Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition–Induced Hypertension. Hypertension, 2021, 77, 1591-1599.	1.3	13
10	THE EFFECTS OF ALIROCUMAB VERSUS EZETIMIBE ON TOP OF STATINS ON VASCULAR INFLAMMATION AND FUNCTION. Journal of the American College of Cardiology, 2021, 77, 159.	1.2	8
11	Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis. BJGP Open, 2021, 5, BJGPO.2021.0094.	0.9	7
12	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102035.	1.1	9
13	Diagnosis of patients with heart failure with preserved ejection fraction in primary care: cohort study. ESC Heart Failure, 2021, 8, 4562-4571.	1.4	2
14	Innate Lymphoid Cells Promote Recovery of Ventricular Function After MyocardialÂInfarction. Journal of the American College of Cardiology, 2021, 78, 1127-1142.	1.2	27
15	muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 690.	0.7	14
16	Advances in PET to assess pulmonary inflammation: A systematic review. European Journal of Radiology, 2020, 130, 109182.	1.2	10
17	Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease. Journal of Nuclear Medicine, 2020, 61, 1701-1707.	2.8	8
18	Left atrial mechanics and aortic stiffness following high intensity interval training: a randomised controlled study. European Journal of Applied Physiology, 2020, 120, 1855-1864.	1.2	5

#	Article	IF	CITATIONS
19	Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 626.	0.7	32
20	ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 604.	0.7	2
21	Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. PLoS ONE, 2020, 15, e0228940.	1.1	13
22	Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study. BMJ Open, 2020, 10, e038360.	0.8	8
23	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Frontiers in Pharmacology, 2020, 11, 580560.	1.6	3
24	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. Journal of Drug Assessment, 2019, 8, 167-174.	1.1	1
25	Non-invasive measurements of arterial function: What? When? Why should we use them?. Heart, 2019, 105, heartjnl-2018-312970.	1.2	6
26	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. Scientific Reports, 2019, 9, 19934.	1.6	14
27	Antiâ€lLâ€7 receptor α monoclonal antibody (CSK2618960) in healthy subjects – a randomized, doubleâ€blind placeboâ€controlled study. British Journal of Clinical Pharmacology, 2019, 85, 304-315.	'1.1	36
28	Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. American Journal of Cardiovascular Drugs, 2019, 19, 335-342.	1.0	88
29	Reproducibility of compartmental modelling of 18F-FDG PET/CT to evaluate lung inflammation. EJNMMI Physics, 2019, 6, 26.	1.3	4
30	Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study. Thorax, 2018, 73, 1182-1185.	2.7	9
31	Surrogate Markers of Cardiovascular Risk and Chronic Obstructive Pulmonary Disease. Hypertension, 2018, 71, 499-506.	1.3	29
32	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. Frontiers in Pharmacology, 2018, 9, 1301.	1.6	2
33	P29 MECHANISMS OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION INDUCED HYPERTENSION. Artery Research, 2018, 24, 87.	0.3	0
34	GLPâ€l Is a Coronary Artery Vasodilator in Humans. Journal of the American Heart Association, 2018, 7, e010321.	1.6	16
35	Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. BMJ Open, 2018, 8, e022452.	0.8	83
36	A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. American Heart Journal, 2018, 204, 102-108.	1.2	11

#	Article	IF	CITATIONS
37	Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease. Respiratory Research, 2018, 19, 100.	1.4	23
38	The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. PLoS ONE, 2018, 13, e0194197.	1.1	23
39	Quantification of Lung PET Images: Challenges and Opportunities. Journal of Nuclear Medicine, 2017, 58, 201-207.	2.8	55
40	Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation. EJNMMI Research, 2017, 7, 47.	1.1	23
41	Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. Chest, 2017, 151, 555-563.	0.4	62
42	[Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. Frontiers in Neuroscience, 2017, 11, 92.	1.4	46
43	Late Breaking Abstract - Co-morbid disease clusters in chronic obstructive pulmonary disease: the ERICA study. , 2017, , .		Ο
44	Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. British Journal of Clinical Pharmacology, 2016, 81, 971-979.	1.1	122
45	12.6 THE ROLE OF NEURONAL NITRIC OXIDE SYNTHASE IN YOUNG ADULTS. Artery Research, 2016, 16, 78.	0.3	Ο
46	The Role of the Autonomic Nervous System in the Regulation of Aortic Stiffness. Hypertension, 2016, 68, 1290-1297.	1.3	44
47	Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis. Journal of the American Heart Association, 2016, 5, .	1.6	20
48	A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients. , 2016, , .		0
49	A functional imaging study to evaluate aortic inflammation in OSA subjects. , 2016, , .		Ο
50	The role of epoxyeicosatrienoic acids in the cardiovascular system. British Journal of Clinical Pharmacology, 2015, 80, 28-44.	1.1	57
51	S124â€The BODE Index is an independent determinant of arterial stiffness in Chronic Obstructive Pulmonary Disease (COPD): Abstract S124 Table 1. Thorax, 2015, 70, A70.2-A71.	2.7	1
52	Comparison of analysis approaches for multi-level vascular imaging data. Trials, 2015, 16, .	0.7	0
53	1.6 THE BODE INDEX PROGNOSTIC SCORE IS AN INDEPENDENT DETERMINANT OF ARTERIAL STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). Artery Research, 2015, 12, 40.	0.3	0
54	P7.14 SERUM INFLAMMATORY MARKERS ARE POOR PREDICTORS OF VASCULAR INFLAMMATION AND VASCULAR INFLAMMATION DOES NOT DETERMINE AORTIC STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). Artery Research, 2015, 12, 33.	0.3	0

#	Article	IF	CITATIONS
55	Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist. Hypertension, 2015, 65, 834-840.	1.3	131
56	Safety and pharmacology of a soluble epoxide hydrolase inhibitor. , 2015, , .		1
57	Abstract 18188: Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (A1ATD) are Associated With Increased Aortic Inflammation and Stiffness. Circulation, 2015, 132, .	1.6	2
58	Effects of Oral Lycopene Supplementation on Vascular Function in Patients with Cardiovascular Disease and Healthy Volunteers: A Randomised Controlled Trial. PLoS ONE, 2014, 9, e99070.	1.1	101
59	Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2014, 14, 155-165.	1.0	76
60	Value of haemodynamic profiling to the response of antihypertensive therapy. Artery Research, 2014, 8, 189.	0.3	3
61	Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen (â€~EVOLUTION'): Rationale and protocol. Artery Research, 2014, 8, 24.	0.3	9
62	Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. British Journal of Clinical Pharmacology, 2013, 76, 99-106.	1.1	24
63	Response to Letter Regarding Article, "Anti–Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis― Circulation, 2013, 128, e11.	1.6	1
64	Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. Journal of Hypertension, 2013, 31, 77-85.	0.3	101
65	Anti-Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis. Circulation, 2012, 126, 2473-2480.	1.6	196
66	103â€Aortic inflammation is reduced, and paralelles changes in aortic stiffness by anti-TNF α therapy in rheumatoid arthritis. Heart, 2012, 98, A59.2-A59.	1.2	0
67	P4.03 ORAL LYCOPENE SUPPLEMENTATION IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE: A RANDOMISED CONTROLLED TRIAL. Artery Research, 2012, 6, 183.	0.3	0
68	Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. JACC: Cardiovascular Imaging, 2012, 5, 911-922.	2.3	123
69	Increased Incidence of Interatrial Block in Younger Adults with Cryptogenic Stroke and Patent Foramen Ovale. Cerebrovascular Diseases Extra, 2011, 1, 36-43.	0.5	31
70	Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia. Circulation, 2011, 123, 515-523.	1.6	88
71	Simvastatin prevents inflammationâ€induced aortic stiffening and endothelial dysfunction. British Journal of Clinical Pharmacology, 2010, 70, 799-806.	1.1	30
72	3.2 A COMPARISON OF THE VICORDER APPARATUS WITH SPHYGMOCOR DEVICE FOR THE NON-INVASIVE ASSESSMENT OF AORTIC BLOOD PRESSURE: AN INVASIVE VALIDATION STUDY. Artery Research, 2010, 4, 146.	0.3	1

#	Article	IF	CITATIONS
73	Primary prevention of CVD: treating hypertension. Clinical Evidence, 2010, 2010, .	0.2	2
74	The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. British Journal of Clinical Pharmacology, 2009, 68, 518-523.	1.1	10
75	P1.06 THE ACCURACY OF CENTRAL SYSTOLIC BLOOD PRESSURE DETERMINED FROM THE SECOND SYSTOLIC PEAK OF THE PERIPHERAL PRESSURE WAVEFORM. Artery Research, 2009, 3, 162.	0.3	Ο
76	The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. Journal of Hypertension, 2009, 27, 1784-1788.	0.3	62
77	Chapter 1 Aetiology and pathophysiology. , 2009, , .		0
78	Chapter 4 Secondary hypertension. , 2009, , .		0
79	Chapter 6 Special populations. , 2009, , .		0
80	Chapter 8 Hypertension in the 21st century. , 2009, , .		0
81	Chapter 3 Specific investigations for secondary hypertension. , 2009, , .		0
82	Chapter 5 Monogenic syndromes. , 2009, , .		0
83	Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. International Journal of Cardiology, 2008, 129, 399-405.	0.8	46
84	Approximation Algorithms for Network Design with Metric Costs. SIAM Journal on Discrete Mathematics, 2007, 21, 612-636.	0.4	29
85	Role of increased aortic stiffness in the pathogenesis of heart failure. Current Heart Failure Reports, 2007, 4, 121-126.	1.3	8
86	An O (VE) algorithm for ear decompositions of matching-covered graphs. ACM Transactions on Algorithms, 2005, 1, 324-337.	0.9	6
87	Aldehyde Dehydrogenase 2 Plays a Role in the Bioactivation of Nitroglycerin in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1891-1895.	1.1	82
88	An Approximation Algorithm for the Minimum-Cost k-Vertex Connected Subgraph. SIAM Journal on Computing, 2003, 32, 1050-1055.	0.8	69
89	Randomized \$ilde{O}(M(V))\$ Algorithms for Problems in Matching Theory. SIAM Journal on Computing, 1997, 26, 1635-1655.	0.8	28